|
Allergy Therapeutics PLC on Wednesday said its combined phases 1 and 2a trial shows its potential treatment for peanut allergy supports a ‘strong immunomodulating potential’ for the product. Phase 1 trials assess the safety of a potential new treatment, while phase 2a trials determine its efficacy and tolerability at different doses. The Worthing, England-based biotechnology company said VLP Peanut, its new anti-allergy product under testing, shows a ‘significant’ reduction in basophil sensitivity, and that both downward allergen binding to effector cells and increasing immunoglobulin G were statistically significant depending on dosage. An absolute reduction in wheal diameter after skin prick testing, measured one month post-treatment, compared to placebo, was also noted, Allergy Therapeutics said, completing the panel of efficacy biomarkers. The company’s Chief Executive Officer Manuel Llobet said: ‘These interim analysis results...demonstrate clinical proof of concept of the product. In addition to its supportive safety profile, these biomarker results highlight the transformational clinical potential with the unique opportunity to offer a potent immunomodulating treatment option with a limited number of injections, not currently offered by oral immunotherapy nor monoclonal options currently available or under development.’ ‘Coupled with the supportive safety and tolerability data we’ve already shown, the team is very keen on progressing to the phase IIb trial to establish dose-range and efficacy via food challenge,’ he added. Allergy Therapeutics shares were up 2.6% at 12.00 pence each on Wednesday at midday in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
